Alkeia Motley

Alkeia Motley supports the FDA Office of Acquisitions and Grants Services in executing strategic procurement actions that advance the agency’s mission to safeguard public health through innovation in regulatory science. She manages a diverse portfolio of acquisitions focused on high-impact technical services and specialized manufacturing capabilities, ensuring alignment with FDA’s priorities in digital infrastructure, analytical tools, and advanced manufacturing technologies. Her work directly enables the development and deployment of cutting-edge solutions such as digital twins for production processes and secure, scalable software systems that enhance regulatory decision-making. Motley cultivates partnerships with a balanced mix of large-capability vendors and small businesses, emphasizing performance-based outcomes and technical excellence. While she engages with firms possessing deep expertise in custom software development and niche manufacturing, her procurement approach prioritizes vendor agility, cybersecurity compliance, and adherence to FDA-specific regulatory standards. She maintains collaborative relationships with contractors capable of delivering secure, validated systems that meet the unique demands of federal life sciences oversight. Her contracting patterns reflect a strong commitment to socioeconomic diversity, with approximately half of her acquisitions structured as total small business set-asides under FAR 19.5, ensuring equitable access for qualified small firms. She actively promotes participation from small businesses without favoring specific socioeconomic categories, creating a level playing field grounded in capability and capacity rather than certification alone. Motley’s primary procurement focus lies in NAICS 541511 (Custom Computer Programming Services) and 339999 (All Other Miscellaneous Manufacturing), reflecting her specialization in bespoke software solutions for regulatory analytics and specialized, low-volume manufacturing of components critical to medical product development. She routinely sources advanced digital tools, data modeling platforms, and precision-manufactured prototypes that support FDA’s modernization initiatives in regulatory science and product evaluation.